AMPH (Amphastar Pharmaceuticals) Momentum Rank: 2 (As of Aug. 26, 2026) — 67% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMPH Amphastar Pharmaceuticals Inc AMPH
79 GF Score
Price $21.96
GF Value $35.83
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Momentum Rank?

Amphastar Pharmaceuticals AMPH +2.07% 79 Momentum Rank is 2 as of Aug. 26, 2026, which is 67% below its 10-year median of 6.00. GuruFocus rates AMPH with a GF Score™ of 79/100 and a GF Value™ of $35.83 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Amphastar Pharmaceuticals has the Momentum Rank of 2.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Amphastar Pharmaceuticals Momentum Rank Related Terms

AMPH vs ESPR, NIKA, BIOA: Momentum Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amphastar Pharmaceuticals Momentum Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Momentum Rank falls into.


AMPH
79GF Score
Amphastar Pharmaceuticals Inc AMPH
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 2 mean?
Amphastar Pharmaceuticals (AMPH) has a Momentum Rank of 2 as of Aug. 26, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Amphastar Pharmaceuticals and its competitors. This is 67% below median its historical median of 6.00. Over the past decade, Amphastar Pharmaceuticals' Momentum Rank has ranged from 2.00 to 10.00.
Is Amphastar Pharmaceuticals' Momentum Rank too high?
Amphastar Pharmaceuticals' current Momentum Rank of 2 is 67% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Amphastar Pharmaceuticals has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Momentum Rank compare to ESPR and NIKA?
Amphastar Pharmaceuticals' Momentum Rank of 2 can be compared against companies in the Drug Manufacturers industry. Historically, Amphastar Pharmaceuticals' own Momentum Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Drug Manufacturers company?
A good Momentum Rank depends on the Drug Manufacturers industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Momentum Rank is 2, which is 67% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.83, compared to a current price of $21.96 — trading 38.7% below its estimated fair value. The current Momentum Rank is 2, which is 67% below median its 10-year median of 6.00. Amphastar Pharmaceuticals' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Momentum Rank is 2 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $21.96 is trading 38.7% below its estimated GF Value™ of $35.83. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Momentum Rank: 2 (67% below median its 10-year median of 6.00)
  • GF Value™: $35.83 vs. price of $21.96 (38.7% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
79GF Score

Get the complete analysis for AMPH

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.96
Price
$35.83
GF Value